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This report derived from the dermatological workshop discusses the problems and issues in the development and optimization 
of topical therapeutic drug products. It provides a clear understanding and differentiation between transdermal and dermal 
products. The report also discusses the hioavailahility/hioequivalence issues for topical therapeutic products. 
Introduction 
The overall purpose of the Workshop held 
during March 26-28, 1990, in Crystal City, VA, 
was to review the relevant literature and discuss 
the problems and issues in the development and 
optimization of topical therapeutic products in 
order to define the state-of-the art of formulation 
practice. The workshop, co-sponsored by the U.S. 
Food and Drug Administration (FDA) and the 
American Association of Pharmaceutical Scien- 
tists (AAPS), was co-organized by scientists from 
the FDA, academia and the pharmaceutical in- 
dustry (Appendix 1). An important goal was to 
establish a consensus on the present problems in 
measuring topical drug delivery. It is hoped that 
these problems can be addressed in the subse- 
quent workshops. 
The major objectices of the workshop were: 
(1) To review and evaluate available informa- 
tion on topical drug products. 
(2) To evaluate relationships between pharma- 
cological activity, drug delivery and clinical effi- 
cacy. 
(3) To identify ways to optimize topical drug 
delivery to target sites. 
(4) To identify important principles in the de- 
velopment and optimization of topical drug prod- 
ucts. 
(5) To raise possible concerns related to the 
local and systemic toxicity problems arising from 
optimization of drug delivery. 
(6) To discuss regulatory concerns in the evalu- 
ation of topical drug products. 
At present, there are no guidelines with regard 
to drug delivery and the assessment and use of 
laboratory models (including animals and mathe- 
matical) to predict and optimize the clinical effi- 
cacy of topical drug products. The current guide- 
lines for bioequivalence assessment suggest stud- 
ies with clinical end points. It is not always practi- 
cal to conduct these studies. It is hoped: (1) that a 
greater understanding of how to conduct system- 
atic and scientific studies to optimize topical 
products will emerge (other than studies with 
clinical end points), so that (2) more reliance can 
be placed on the use of laboratory studies, includ- 
ing those involving the use of animals and in vitro 
studies with animal and human skin and synthetic 
membranes, to understand, develop, optimize and 
compare topical drug delivery systems. 
Differentiating Transdermal and Topical (Der- 
matological) Therapeutic Products 
Transdermal and topical products are increas- 
ing in importance and their use in therapy is 
becoming more widespread. While topical prod- 
ucts to treat dermatological ailments have been in 
existence from the earliest times, transdermal 
products, where skin is used as an alternative 
route for systemic therapy, are relatively new 
therapeutic entities. Even then, the principles 
involved in the development and optimization of 
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transdermal products are far better understood 
than for the topical products. Reasons for this 
are as follows. 
With transdermals, the blood concentration 
needed to achieve therapeutic efficacy is gener- 
ally known. 
Most transdermals operate at relatively even 
thermodynamic activity and therefore the drug 
delivery kinetics of transdermals are actually less 
complicated than for topical dosage forms. 
There has been a tendency amongst re- 
searchers to mix and confuse the principles of 
topical and transdermal delivery. It is critical to 
distinguish the substantial pharmacokinetic and 
clinical (performances differences between topi- 
cal products and transdermal drug delivery sys- 
tems. Transdermal products are designed to de- 
liver drugs through the skin to achieve systemic 
effects, hence skin is not the target. A maxima1 
net drug transport across the skin and a minimal 
skin retention of the drug are the optimal at- 
tributes of a transdermal product. In contrast, a 
topical drug product is designed to deliver drug 
into the skin for treating dermal disorders and 
here skin is the target organ. Non-steady-state 
transport generally characterizes a topical drug 
product. Maximal efficacy and minimal exposure 
to systemic toxicity are among the attributes 
sought for an optimal topical drug product. Defi- 
nitions of some additional terms relevant to 
transdermal and topical products also need clari- 
fication (Appendix 2). 
A topical drug product is applied over the 
diseased skin area as a thin film (typically l-3 ~1 
solution/cm’ or l-3 mg cream or ointment/cm2 
amounting to films from 10 to 30 Frn in thick- 
ness) with a rubbing action. Usually, little visible 
mass remains on the skin following inunction. No 
substantial formulation builds up on the skin 
surface upon repeated application, which is often 
once daily but may be more frequent. In most 
cases, the formulation is left unoccluded. This 
allows the formulation components to evaporate 
and/or be absorbed into the skin or rubbed off 
or sloughed off the skin. Thus, immediately upon 
application, the physicochemical and thermody- 
namic conditions which drive drug delivery change 
radically from when the formulation was first 
applied. In contrast, a transdermal system is a 
prefabricated device in which drug is incorpo- 
rated into some sort of reservoir, in some in- 
stances a ‘pouch’, in others a dispersion in a 
polymer layer and in yet others a dispersion in 
the adhesive. This device or patch is fastened 
adhesively to the skin surface. Rarely is the ma- 
trix containing drug exposed to the atmospheric 
conditions. There is some conditioning of the 
application (patch) by insensible perspiration but, 
for the most part, the physicochemical and ther- 
modynamic conditions remain constant and thus 
provide a nearly constant rate of drug delivery 
through the skin. At least one transdermal system 
has been designed such that the rate of drug 
release from the patch onto the skin surface is 
slower than the permeation of the drug through 
the skin. Consequently, this transdermal product 
controls the rate and extent of drug delivery to 
the systemic circulation. 
Since percutaneous absorption is common to 
both topical and transdermal products, there has 
been a tendency to view this event as being of 
comparable significance in each of these delivery 
modalities. Therefore, mistakenly, the sole basis 
of drug delivery performance has been the drug 
flux across the skin and has been without proper 
regard for disposition of the drug in the local 
tissue. 
For a transdermal product, an optimal drug 
flux across the skin without appreciable drug 
build-up in the skin is ideal. For topical (dermato- 
togical) products, an optical drug build-up in the 
skin with little or no drug flux through the skin is 
most ideal. Since the drug concentration rarely 
remains constant in the case of a topical formula- 
tion applied on the skin, the situation for derma- 
tological products is far more complicated than 
seen with most transdermal drug delivery sys- 
tems. Topical formulations usually contain sev- 
eral excipients; these also partition into the skin 
in accordance with their physicochemical proper- 
ties. Certain excipients change the integrity of the 
stratum corneum. When this occurs, the solubiiity 
of compounds within the horny layer and/or the 
ease with which they diffuse through this tissue 
are affected. Some components including drugs 
(e.g., nitroglycerin) occasionally evaporate away 
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during the course of delivery, systematically alter- 
ing the drug’s activity in the remaining vehicle. 
For unstable drugs, exposure to air and light can 
be a problem. Given such issues, drug delivery 
into and retention in the skin are not well re- 
flected by steady-state flux data. This means that 
drug localization within the skin depends upon 
the unique properties of the formulations and 
may not relate well to in vitro flux data as mea- 
sured, for example, in diffusion cells. Depending 
upon the specific formulation used, a high degree 
of drug accumulation in the skin may be achieved 
even at low flux values. Consequently, it is criti- 
cally important that the topical drug delivery be 
viewed differently from transdermal delivery. In 
particular, emphasis should be placed on drug 
retention in the skin for dermatological products 
as opposed to drug flux across the skin for trans- 
dermal delivery systems. 
Problems in the Development and Optimization 
of Dermatological Products 
Puthophysiology of the skin und target sites 
The pathophysiology of the skin and its effects 
on the barrier properties of skin are quite rele- 
vant to the understanding of topical drug deliv- 
ery. Thus, only with a thorough mechanistic un- 
derstanding of the drug uptake process can opti- 
mal drug delivery systems be designed. This 
knowledge is necessary in establishing models to 
evaluate formulations. In particular, in animal 
models the skin should have drug uptake proper- 
ties which are comparable to those of the human 
skin condition which is to be treated. An animal 
model can only be considered predictive under 
these conditions. 
Another important consideration is the site of 
action of a drug in the skin. Drug delivery from 
topical products should ideally be directed to 
specific skin targets within its multiple layers to 
be optimally effective. However, targeting of drugs 
to a particular cutaneous tissue, e.g., the basal 
epidermis or fibroblasts in the dermis, cannot be 
accomplished without also involving surrounding 
tissues, and thus effective and sustained rate of 
delivery needs to be sought to provide optimal 
therapy. Ideally, one would like to deliver the 
exactly correct amount of drug exclusively to spe- 
cific cellular targets. Drug targeting to specific 
cells within the skin structures promises to be an 
extremely complex issue which to date is without 
precedent. The problem is complicated by the 
fact that for many dermal conditions the target 
sites and local mechanisms of drug action remain 
unknown. A greater knowledge of all aspects of 
skin pharmacology will assist in the development 
of meaningful approaches here. Close working 
relationships among drug delivery scientists. 
pharmacologists, toxicologists and clinical scien- 
tists are essential for developing target specific 
dermatological products. 
Screening of dwgs und their derirutilles for relutir)e 
pharmacological uctirities 
In the pre-developmental phase for new chem- 
ical entities, many drugs and derivatives arc 
screened for relative pharmacological activities. 
Generally, a simple vehicle, often acetone, is used 
as the solvent in the screening process without 
due concern about the effect vehicles have on 
drug delivery. This approach presents the risk of 
selecting suboptimal compounds or rejecting po- 
tentially effective compounds in the screening 
process. A better approach would be to develop a 
first generation formulation with an eye to the 
physicochemical properties of the drug candidate 
and aspects of delivery to the target discasc. 
The del~elopmentul process for dertnutologicul 
prodrlcts 
Some of the key decisions and activities spe- 
cific to developing a drug into a marketable topi- 
cal product include: 
Selecting the dosage form(s) most suited to 
treating the disease or condition. One or another 
of a cream, ointment, lotion, solution. gel, 
spray/aerosol, plaster, etc., might bc most appro- 
priate in a given situation. 
Preparation of prototype formulations. 
Developing analytical methods to assay drug in 
the formulations and in the skin layers. 
Assessment of drug uptake in skin and percu- 
taneous transport in vitro and/or in vivo. 
Assessing the potential for cutaneous toxicity 
(e.g., irritation, sensitization). 
~icrobia1 testing and selection of formulation 
preservatives. 
Testing for cosmetic/aesthetic qualities. 
Performance of phase 1-3 clinical studies. 
Scale-up for large-scale manufacturing, 
preparing stability batches and developing pro- 
cess documentation. 
Developing appropriate quality control tests. 
Quite often, drug formulations for clinical test- 
ing are selected without due consideration of 
optimization of drug uptake/retention in skin. 
Formulation development is not conducted by 
optimizing drug delivery to the. target site despite 
the fact that this may be pivotal to the success of 
a topical product. In some cases, formulations are 
evaluated for the drug flux across the skin, and 
the formulations exhibiting maximal fluxes are 
selected for further testing. The correct criterion 
for selecting optimal formulation of topical drugs, 
however, should be achieving optimal drug up- 
take/retention in specific regions of the skin, 
and not necessarily high flux per se. These two 
parameters, retention and flux of a drug, may or 
may not be related. When a topically applied 
drug is ineffective in clinical trials, we presently 
cannot determine whether it is inherently inactive 
or whether its delivery was insufficient. Knowl- 
edge of the drug’s local tissue concentration of- 
fers a parameter which can be used to make this 
differentiation and to further optimize the formu- 
lation and reevaluate it for clinical efficacy. Un- 
fortunately, rarely if ever do we know the effec- 
tive drug concentration in the skin. It is hoped 
that as we learn more about the developmental 
aspects, ways will be found to fill in such a critical 
knowledge base. meanwhile, in the absence of 
such information, the prudent development sci- 
entist should pursue all reasonable means to opti- 
mize skin uptake/ retention before evaluating the 
clinical activity of the drug. The following issues 
and questions should be raised during the devel- 
opmental process for topical drug product: 
Are the physicochemical properties of the drug 
in question sufficiently well understood? 
Has the pharmacological activity of the drug 
been either demonstrated or adequately pre- 
dicted? 
Are the pharmacological models used in as- 
sessing/ predicting the drug’s pharmacological 
activity relevant and we11 conducted? 
What research vehicles were used in screening 
the drug for pharmacological activity? Were these 
relevant and appropriate? 
Is the target tissue for the drug known? Is this 
the epidermis, dermis or some specific cellular 
group within these strata? 
Has drug delivery and specifically drug up- 
take/retention within the skin’s layers been ade- 
quately evaluated? 
Critical Considerations in Drug Uptake Studies 
in Skin and Correlation to Clinical Efficacy 
Drug uptake studies in skin 
The critical issues involved in conducting drug 
uptake and retention studies in the skin for topi- 
cal formuIations include the following. 
What experimental tissue should be used? In in 
vitro studies should human cadaver skin or ani- 
mal skin be used? This is still an area of research 
and exploration. 
~ho~~fd stl~dies be in tlitro or in siso and birder 
what ~~rc~~?zstance~~? Information is needed to 
establish the correlation between data on drug 
retention in skin for in vitro and in vivo studies. 
Whut are the time dependences of local drug 
delirjery and retention? How does the dosing reg- 
imen affect retention of a drug in the skin? The 
kinetics of drug retention from single and multi- 
ple dose applications are important and should 
be given critical consideration in deciding the 
dosage regimen of the product. For evaluating 
new drugs for clinical efficacy, a knowledge of 
drug retention kinetics may be important in de- 
signing clinical protocols. 
What techniques are best to evaluate drug up- 
take in the skin? A review of the literature indi- 
cates that several types of apparatus and proce- 
dures are claimed to be useful in conducting drug 
permeation and in some cases drug retention 
studies in skin. The tendency has been to use 
steady-state permeation procedures for topicals, 
though these are only really interpretable in the 
instance of transdermal products. Generally, for 
topical products, finite dose procedures should be 
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employed and a formulation should be applied at 
a level of l-3 mg or ~1 of the product per cm2 of 
the skin, usually with inunction. The skin should 
be left open to the atmospheric conditions if this 
mimics the clinical use situation. 
How does cleansing the skin surface ajfect ap- 
parent drug delir!ery and retention? The cleans- 
ing procedure is another critical experimental 
variable which needs a research definition. Typi- 
cally, a formulation is applied on the skin as a 
finite dose. After a certain time, excess formula- 
tion is removed from the skin surface before 
determining the drug levels in the skin layers. 
There is no uniform, validated procedure to 
achieve this purpose. Rather, the procedures in- 
clude washing the skin with: (1) small portions of 
volatile solvents such as methanol, ethanol or 
acetone; or (2) aqueous solutions of detergents. 
The possibility that such cleansing procedures 
will influence the experimental results is real, 
considering that most of the drug applied on the 
skin normally remains on, or at least near the 
skin’s surface. Therefore, even a slightly incom- 
plete wash can result in a large error in estimat- 
ing skin retention. On the other hand, too vigor- 
ous a procedure runs the risk of extracting drug 
which otherwise would be retained in the skin 
layers. A validated wash procedure needs to be 
developed for use in drug retention studies in 
skin. 
What analytical procedure is to he used:) An- 
other critical issue is to develop a specific and 
sensitive analytical procedure, preferably one 
which is chemically specific such as an HPLC 
method, for determining low levels of drug in the 
epidermis or dermis. Radioisotopic methods may 
be used, but one must recognize that these arc 
not favored for human research and often lack 
molecular specificity. 
How should data be presented? Data presen- 
tation and interpretation also become critical is- 
sues. There are no established precedents for 
analysing skin retention data. Should retention 
results be expressed in terms of the amount of 
drug per unit area of the skin or in terms of the 
amount of drug per unit weight of the respective 
skin layer? The latter makes more sense because 
it is the drug concentration which is important 
and related to pharmacological activity. One 
would thus need to know the masses of the skin’s 
layers. Stratum weights depend on several factors 
including age, gender, weight and the anatomical 
site of the human or other animal used. For data 
reproducibility, controls may need to bc placed 
on these factors. On the other hand, in conduct- 
ing drug uptake studies in humans using skin 
stripping procedures, results are often expressed 
in amount per unit area. Howcvcr, expressing it 
in terms of drug amount per unit weight of the 
skin layer is desirable. 
What are the influences of formulation, applica - 
tion and subject factors on drug delil>ev? The 
effects of some pertinent factors such as drug 
concentration, total dose, thickness of applica- 
tion, pH of the formulation, drug lipophilicity, 
vehicle lipophilicity, temperature, hydration/ 
occlusion and the patient’s age/ gender/ 
anatomical site on retention of drugs in skin 
deserve extensive study. 
Use of’ enhancers 
A review of the literature might lead one to 
conclude that enhancer effects have been thor- 
oughly studied. However. most of these data pcr- 
tain to the enhancement of flux or permeation 
across the skin, a parameter of direct importance 
for transdermal products. How enhancers affect 
local deposition of drugs, on the other hand, is 
not well known and studied. It is important that 
enhancement for topical products be studied for 
drug retention in the skin as enhanced perme- 
ation does not necessarily mean that there will be 
better targeting of the drug. As has been men- 
tioned earlier, permeation is not a relevant pa- 
rameter for the optimization of topical drug de- 
livery. 
Clinical correlations 
How drug rctcntion in the skin relates to clini- 
cal efficacy is another important consideration in 
drug uptake studies in skin. In principle, since a 
dermatological drug is meant to ameliorate a skin 
disease, optimization of drug uptake/ retention 
pattern in the skin therefore should provide an 
optimal therapeutic effect. However, there are no 
explicit examples to prove this contention. Gath- 
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ering such information would not only produce 
optimal products, but also would assist in learn- 
ing about the specific target sites. Clinical effi- 
cacy may vary with drug retention in the skin in a 
linear or asymptotic manner. If the profile is 
linear, the product can still be further optimized. 
On the other hand, if a plateau is reached in 
clinical efficacy, further optimization of drug re- 
tention in skin is unnecessary and indeed may 
increase the risk of local or systemic toxicity. 
Regulatory Considerations 
Bioacailability and bioequicalence issues 
The issues of bioavailability and bioequiva- 
lence were given considerable thought at the 
workshop. Since the target organ for topical 
products is skin, it seems logical that determining 
drug concentrations in the skin layers should pro- 
vide an assessment of topical bioavailability. Pre- 
liminary work on glucocorticoids indicates that 
the drug concentration in the stratum corneum 
(obtained by the skin stripping technique) can be 
correlated to the pharmacodynamic response and 
that the drug concentration may be used to esti- 
mate bioavailability of the product. More work in 
this area is needed to establish procedures for 
assessing bioavailability of topical dermatological 
products. Using the skin stripping technique, only 
stratum corneum is readily accessible and the 
deeper tissues, e.g., viable epidermis and dermis, 
are beyond reach. The skin stripping technique 
thus is subject to the criticism that, in many cases, 
the drug concentration at the site of action is not 
measured and may not correlate with the 
bioavailability and bioequivalence of topical 
dosage forms. 
At present, there are no accepted nonclinical 
models or approaches to predict or determine the 
bioavailability and bioequivalence of dermatologi- 
cal drugs. Consequently, bioequivalence assess- 
ment of test and reference product is based on 
studies with clinical end points or pharmacody- 
namic measurements such as blanching assay for 
glucocorticoids. This raises the problem of how to 
ensure bioavailability and bioequivalence where 
(1) minor formulation changes are involved and 
(2) process changes are involved during scale-up. 
Can in vitro and/or in vivo drug uptake studies 
in skin answer these questions? Reliable data are 
not available to support any such approach. Us- 
ing a theoretical approach, it may prove possible 
to develop mathematical models to predict drug 
retention based on experimental information for 
a given drug. This so-called C* approach (drug 
concentration at the target site) is worthy of 
further pursuit. 
Quality control issues 
At present, no recognized quality control pro- 
cedure is available for assessing batch-to-batch 
uniformity of dermatological products in terms of 
drug release. A simple procedure to determine 
the drug release rate from the cream formula- 
tions using commercially available diffusion cell 
and synthetic membrane has been suggested as a 
means of accomplishing this, but it is clear that 
this approach needs to be carefully validated be- 
fore it can be recommended and widely imple- 
mented. 
Since drug must first be released from the 
formulation and then permeate through the stra- 
tum corneum for therapeutic effect, it may be 
appropriate to use drug release properties em- 
ploying synthetic membrane techniques as a qual- 
ity control test to ensure batch-to-batch uniform- 
ity. The quality control test should be able to 
detect formulation or process factors which may 
affect the bioavailability and bioequivalence of 
the drug product. 
Disclaimer 
This report contains the personal opinions of 
the authors and does not necessarily represent 
the views or policies of the American Association 
of Pharmaceutical Scientists or the U.S. Food 
and Drug Administration. In particular, the re- 
port should not be construed as a guideline of the 
U.S. Food and Drug Administration. 
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Appendix 2: Terminology 
Permeation Net transport of drugs across the 
skin. A relevant parameter in trans- 
dermal drug delivery. 
Retention Drug residence in the skin or its 









A relevant term in topical drug de- 
livery. 
Capable of being permeated, e.g., 
skin 1 is more permeable than skin 
2. Also, capable of permeating the 
skin, e.g., drug 1 is more permeable 
than drug 2. 
Capable of retaining substances in 
the skin. Also, capable of being re- 
tained in the skin. 
A quantifiable term which dcscribcs 
the degree to which a skin is perme- 
able. 
A quantifiable term which describes 
the degree to which a skin is rcten- 
tive. 
A substance which pcrmcatcs the 
skin. 
A substance which is retained in the 
skin. 
A substance that catalyzes the per- 
meation of another substance across 
a membrane. It is a more specific 
term than enhancer. 
A substance that catalyzes the re- 
tention of another substance in the 
skin. 
A term which some researchers have 
used interchangeably to describe 
drug delivery to or through the skin. 
It causes confusion. 
